Shrimp Disease Diagnostics Market By Diagnostic Method (PCR & qPCR, Isothermal Amplification, Immunoassays, Microscopy & Histopathology, Culture-Based & Biochemical Tests, Other Diagnostic Methods); By Disease Type (White Spot Syndrome Virus [WSSV], Acute Hepatopancreatic Necrosis Disease [AHPND], Enterocytozoon hepatopenaei [EHP], Infectious Hypodermal and Hematopoietic Necrosis Virus [IHHNV], Yellow Head Virus [YHV], Other Shrimp Diseases); By End User (Shrimp Farms, Hatcheries, Diagnostic Laboratories, Research Institutes, Government & Regulatory Laboratories); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Shrimp Disease Diagnostics Market – From Outbreak Response to Proactive Biosecurity Intelligence

The Global Shrimp Disease Diagnostics Market was valued at USD 0.44 billion in 2025 and is projected to reach USD 0.87 billion by 2032, expanding at a CAGR of 10.2% during 2026–2032.

 

Shrimp disease diagnostics covers molecular, microscopic, microbiological, and field-deployable methods used to identify pathogens that can affect hatchery performance, survival rates, growth, and farm productivity. Commercially important targets include White Spot Syndrome Virus (WSSV), Enterocytozoon hepatopenaei (EHP), Acute Hepatopancreatic Necrosis Disease (AHPND), IHHNV, IMNV, yellow head virus, and other emerging pathogens.

 

Market demand is increasingly being driven by preventive biosecurity rather than post-outbreak investigation alone. Hatcheries and farms are incorporating testing into broodstock selection, post-larvae stocking, animal movement, harvest planning, and disease-containment decisions. This is making diagnostics a more routine part of shrimp production, particularly in regions where disease outbreaks can cause significant economic losses.

 

PCR remains the primary laboratory testing platform, supported by its sensitivity and ability to detect infections before visible symptoms appear. Multiplex PCR is gaining wider interest because several pathogens can be screened in a single workflow, helping laboratories improve throughput and reduce testing time. LAMP and emerging CRISPR-based assays are also supporting the development of faster, field-oriented testing closer to hatcheries and farms.

 

Histopathology and microscopy continue to play an important role in disease confirmation and broader animal-health assessment. At the same time, portable testing kits, simplified sampling systems, and local diagnostic services are improving access for smaller producers.

 

How Is Disease Surveillance Converting Shrimp Outbreak Risk into Recurring Diagnostic Demand?

WSSV remains one of the strongest commercial reasons for recurring shrimp diagnostics because earlier detection gives producers more opportunity to isolate affected stocks, modify farm operations, and reduce the risk of pathogen spread. India's national surveillance system demonstrates how testing is becoming institutionalized rather than remaining an outbreak-only service.

The Government of India has strengthened shrimp disease surveillance through fortnightly aquaculture sampling in Andhra Pradesh and nationwide monitoring under the Rs. 33.78 crore ICAR-NBFGR programme, with WSSV detections recorded through both passive and active surveillance. Alongside WSSV, EHP has become a key concern due to its impact on shrimp growth and production efficiency, driving routine laboratory and hatchery screening beyond outbreak response. Additionally, diseases such as AHPND, IHHNV, IMNV, YHV, DIV1, and other emerging pathogens are expanding diagnostic requirements as producers increasingly rely on updated testing tools to manage evolving disease risks.

 

How Are WOAH Standards and Shrimp Biosecurity Rules Affecting Diagnostic Testing Demand?

WOAH's Aquatic Animal Health Code and Manual of Diagnostic Tests for Aquatic Animals provide internationally recognized approaches for surveillance and laboratory diagnosis of listed aquatic diseases. The Aquatic Manual establishes standardized diagnostic methods for laboratories, while WOAH also maintains a register of diagnostic kits evaluated for defined purposes. The online WOAH standards were updated in September 2025, keeping aquatic disease diagnosis aligned with current international animal-health requirements.

India's Coastal Aquaculture Authority framework converts disease surveillance into recurring testing requirements. Current guidelines require in-house health monitoring and disease surveillance and specify screening of broodstock and parental post-larvae through PCR, histopathology, or other appropriate advanced techniques. Molecular screening is required to follow procedures in the latest WOAH Manual of Diagnostic Tests for Aquatic Animals.

CAA rules also make registration central to commercial coastal aquaculture oversight. Shrimp farms are required to register with the Authority, while hatcheries producing L. vannamei seed must meet requirements associated with SPF broodstock. India's rules also require quarantine of imported shrimp broodstock and parental post-larvae, linking international stock movement directly with pathogen-exclusion and testing infrastructure.

 

Why Do PCR, Multiplex Testing, Histopathology, and Rapid Tests Have Different Commercial Roles?

PCR and real-time PCR remain central to commercial shrimp pathogen surveillance because they provide sensitive pathogen-specific detection and can be standardized across laboratories. They are particularly valuable when testing apparently healthy broodstock or post-larvae where pathogen levels may be too low for visual assessment.

Histopathology remains relevant alongside molecular diagnostics because pathogen DNA or RNA detection does not necessarily establish the extent of tissue damage or determine whether a detected organism explains the production problem. This creates complementary demand for molecular testing and pathology rather than making PCR a complete replacement for microscopic evaluation.

Field diagnostics address another purchasing requirement: farms that need an actionable answer without sending every specimen to a centralized laboratory. WOAH's register includes the Innocreate Bioscience WSSV RP Rapid Test Kit for qualitative WSSV detection in shrimp. WOAH validation information indicates that its performance is strongest in moderate and heavy infections or symptomatic shrimp, which preserves an important role for laboratory molecular assays where low-level infection needs to be detected.

Multiplex testing addresses cost and workflow complexity by expanding the number of pathogens assessed from a common sample. As farms screen broodstock and post-larvae for broader pathogen sets, the competitive advantage shifts from simply offering PCR toward providing greater target coverage, reproducible results, efficient sample logistics, and actionable reporting.

 

How Is the Shrimp Disease Diagnostics Market Structured Across Key Categories?

Market Breakdown by Diagnostic Method

PCR & qPCR represented an estimated 42.0% of the market, equivalent to USD 0.185 billion in 2025, and is projected to expand at a CAGR of 10.2%. The segment remains the largest because PCR-based methods are widely used for sensitive pathogen confirmation, broodstock screening, post-larvae testing, surveillance, and laboratory-based disease investigation.

Isothermal Amplification accounted for an estimated 16.0% share, or USD 0.070 billion in 2025, and is projected to register the fastest growth within the diagnostic-method category at a CAGR of 13.2%. LAMP and other isothermal approaches are gaining relevance where rapid testing is required without the complete thermal-cycling infrastructure associated with conventional PCR systems.

Immunoassays represented approximately 12.0% of the market, or USD 0.053 billion in 2025, with an estimated CAGR of 10.8%. Their role is concentrated in comparatively rapid and accessible screening applications where ease of use and turnaround time are important.

Microscopy & Histopathology accounted for approximately 11.0% of the market, equivalent to USD 0.048 billion in 2025, and is projected to grow at a CAGR of 7.8%. These methods remain important for tissue-level disease assessment and confirmatory investigations, particularly when molecular detection needs to be interpreted alongside pathological changes.

Culture-Based & Biochemical Tests represented an estimated 10.0% share, or USD 0.044 billion in 2025, and are projected to expand at a CAGR of 7.2%. Their use remains relevant for bacterial investigations and laboratory characterization, although longer turnaround requirements limit growth relative to faster molecular platforms.

Other diagnostic methods accounted for the remaining 9.0% of the market, equivalent to USD 0.040 billion in 2025, and are projected to grow at a CAGR of 9.4%.

PCR-based methods therefore continue to dominate shrimp-pathogen confirmation and surveillance, while isothermal amplification is expected to record stronger growth as producers and laboratories seek faster and more deployable testing options.

 

Market Distribution by Disease Type

White Spot Syndrome Virus (WSSV) represented the largest disease-specific segment, accounting for an estimated 28.0% of the market, or USD 0.123 billion in 2025, and is projected to expand at a CAGR of 9.6%. Its leading position reflects the continuing importance of WSSV surveillance across major shrimp-producing countries and its role in farm, hatchery, and regulatory testing programs.

Acute Hepatopancreatic Necrosis Disease (AHPND) accounted for approximately 22.0% of the market, equivalent to USD 0.097 billion in 2025, and is projected to grow at a CAGR of 10.6%. Testing demand is supported by continued surveillance in intensive shrimp-production systems where early identification can influence stocking and farm-management decisions.

Enterocytozoon hepatopenaei (EHP) represented approximately 19.0% of the market, or USD 0.084 billion in 2025, and is projected to record the fastest growth among the major disease categories at a CAGR of 12.8%. EHP testing is becoming increasingly important because infections can affect growth and production consistency even without the severe mortality patterns associated with some viral diseases.

Infectious Hypodermal and Hematopoietic Necrosis Virus (IHHNV) accounted for an estimated 11.0% share, equivalent to USD 0.048 billion in 2025, and is projected to expand at a CAGR of 8.2%.

Yellow Head Virus (YHV) represented approximately 8.0% of the market, or USD 0.035 billion in 2025, with an estimated CAGR of 7.5%.

Other shrimp diseases, including emerging viral, bacterial, and other pathogen targets, collectively accounted for approximately 12.0% of the market, equivalent to USD 0.053 billion in 2025, and are projected to expand at a CAGR of 10.0%.

WSSV remains the largest disease-specific testing segment, while the comparatively stronger modeled growth of EHP and AHPND diagnostics reflects increasing surveillance of production losses that are not limited to acute viral mortality events.

 

End Users Account for the Largest Diagnostic Demand

Shrimp Farms represented the largest end-user segment, accounting for an estimated 40.0% of the market, or USD 0.176 billion in 2025, and are projected to expand at a CAGR of 10.5%. Farms generate recurring demand through pond surveillance, abnormal-growth investigations, stock movement decisions, and testing associated with disease-management programs.

Hatcheries accounted for approximately 23.0% of the market, equivalent to USD 0.101 billion in 2025, and are projected to record the fastest end-user growth at a CAGR of 11.4%. Hatcheries increasingly use diagnostic screening to protect broodstock and post-larvae quality before seed enters commercial grow-out systems, making early-stage testing commercially important.

Diagnostic Laboratories represented approximately 18.0% of the market, or USD 0.079 billion in 2025, and are projected to grow at a CAGR of 10.2%. Their role is supported by demand for PCR, qPCR, multiplex assays, histopathology, confirmatory testing, and sample processing from farms, hatcheries, and regulatory programs.

Research Institutes accounted for approximately 10.0% of the market, equivalent to USD 0.044 billion in 2025, and are projected to expand at a CAGR of 8.2%. Demand is concentrated in pathogen characterization, assay development, surveillance research, and emerging-disease investigation.

Government & Regulatory Laboratories represented approximately 9.0% of the market, or USD 0.040 billion in 2025, and are projected to grow at a CAGR of 8.4%. These laboratories support disease surveillance, quarantine, certification, reference testing, and national aquatic-animal-health programs.

Shrimp farms remain the largest source of diagnostic demand, while hatcheries are expected to grow more rapidly as pathogen screening moves earlier into broodstock, seed-production, and post-larvae qualification workflows.

 

How Is the Shrimp Disease Diagnostics Market Performing Across Different Regions?

Asia-Pacific as the Primary Growth Driver of the Shrimp Disease Diagnostics Market

Asia-Pacific represents the strongest concentration of diagnostic demand, accounting for 55.0% of the market, equivalent to USD 0.242 billion, and is projected to grow at a CAGR of 10.4%, because the region combines intensive shrimp farming, extensive hatchery networks, large numbers of individual farms, and formal disease-surveillance programs.

India shows the scale of organized shrimp diagnostics, with MPEDA maintaining a database of nearly 70,000 aquaculture farms and CAA rules enforcing disease monitoring and farm registration. The MPEDA-RGCA Aquatic Quarantine Facility also acts as a key checkpoint for SPF broodstock entering hatcheries.

The Government of India’s Rs. 33.78 crore NSPAAD program, along with regular sampling in states like Andhra Pradesh, has created steady demand for PCR-based testing of shrimp and water samples, supporting ongoing use of diagnostic labs, reagents, and testing infrastructure.

Vietnam is another major market, producing about 998,800 tonnes of shrimp in the first nine months of 2025, a 6.3% year-on-year increase. Rising production is increasing the need for hatchery screening, disease surveillance, and stronger diagnostic capacity.

 

Why Latin America Is Becoming an Important Shrimp Diagnostic Market

Latin America accounts for 25.0% of the market, equivalent to USD 0.110 billion, and is projected to grow at a CAGR of 11.1%, making it a key shrimp-producing region, with Ecuador identified by FAO as the world’s largest shrimp exporter and a major driver of global supply, according to GLOBEFISH.

The region’s large-scale farming systems are increasing demand for routine disease testing across hatcheries and farms, not just during outbreaks. Producers are screening broodstock, post-larvae, and grow-out stocks more regularly to reduce production losses.

Diagnostic demand is also rising for multi-pathogen testing. Companies like Genics are active in the region, while studies from the University of Arizona report diseases such as EHP, IHHNV, and IMNV affecting production. This is driving adoption of broader molecular panels instead of single-disease tests like WSSV alone.

 

North America’s Role in the Shrimp Disease Diagnostics Market

North America accounts for an estimated 8.0% of the market, equivalent to USD 0.035 billion, and is projected to grow at a CAGR of 8.4%, while remaining smaller as a commercial shrimp-farming base than Asia-Pacific or Latin America but playing an important role in assay development, reference diagnostics, proficiency testing, and emerging-disease preparedness.

The University of Arizona Aquaculture Pathology Laboratory supports global shrimp health testing by providing PCR, histopathology, and microbiology services, and runs a Ring Test program to improve accuracy in PCR-based pathogen detection across laboratories.

North America also contributes through companies like Thermo Fisher Scientific and U.S. animal-health agencies that monitor emerging crustacean diseases. As a result, the region’s role is focused more on diagnostic tools, reference testing, and research rather than large-scale shrimp production.

 

Europe’s Support for Aquatic Disease Diagnostic Infrastructure

Europe accounts for a 7.0% market share, valued at approximately USD 0.031 billion, and is projected to grow at a CAGR of 8.1%, reflecting its comparatively smaller direct shrimp-farming opportunity but strong contribution to aquatic diagnostic standards, reference-laboratory infrastructure, surveillance, and technology development.

The European Union’s Animal Health Law sets rules for controlling transmissible aquatic diseases, while the European Commission supports reference laboratories for aquatic animal health. The National Veterinary Institute at the Technical University of Denmark acts as the EU Reference Laboratory for crustacean diseases, supporting molecular testing, proficiency checks, and confirmatory diagnostics.

Overall, Europe is a niche but high-standard market where validated testing methods and quality assurance are more important than large-scale shrimp farm screening.

 

The Middle East and Africa Are Emerging as a Specialized Shrimp Diagnostics Opportunity

The Middle East and Africa are still smaller shrimp diagnostics markets than Asia-Pacific, but they are steadily building aquaculture and biosecurity capacity, accounting for a 5.0% market share valued at USD 0.022 billion in 2025 and projected to grow at a CAGR of 9.2%. Saudi Arabia is a key example, with its national aquaculture framework supporting a reference diagnostic laboratory for fish and crustacean diseases, using PCR and histopathology testing.

In May 2026, the Fish Health and Safety Laboratory in Jeddah tested 686 marine and farmed fish samples and issued export health certificates. The facility covers virology, microbiology, histology, and parasitology, highlighting growing regional investment in aquatic disease surveillance infrastructure.

 

How Is Competition Shifting from Single-Pathogen Tests toward Broader Disease-Risk Platforms?

Competition is increasingly determined by pathogen coverage, analytical sensitivity, turnaround time, accreditation, sample logistics, ease of use, and the ability to convert laboratory results into production decisions. No audited public filing identified in this research separately discloses shrimp-diagnostics-specific revenue, making product portfolios and deployment capabilities more useful indicators of competitive positioning than reported company sales.

Genics in the Shrimp Disease Diagnostics Market

Genics is positioned around high-sensitivity multiplex pathogen testing and early disease detection. Its Shrimp MultiPath platform is designed to screen numerous commercially important shrimp pathogens within a common workflow rather than requiring farms to commission multiple independent tests.

Shrimp MultiPath2.0 detects 18 pathogen targets simultaneously and includes important disease agents associated with WSSV, IMNV, EHP, AHPND, IHHNV, and other production threats. Genics also emphasizes replicate testing for each pathogen to increase confidence in low-level detection.

The company's portfolio is positioned beyond reagent supply. Testing, sample logistics, disease monitoring, and digital reporting allow Genics to participate across broodstock screening, hatchery management, post-larvae assessment, and farm surveillance. Its commercial model is therefore aligned with producers seeking a broader health-management service rather than an isolated single-pathogen assay.

 

Thermo Fisher Scientific in the Shrimp Disease Diagnostics Market

Thermo Fisher Scientific participates through molecular testing systems, PCR reagents, laboratory instruments, and animal-health diagnostic products. Its fish and crustacean diagnostic portfolio covers important shrimp pathogens including WSSV and IHHNV.

The company's competitive position is strengthened by its wider Applied Biosystems molecular-testing ecosystem. Laboratories that already operate real-time PCR instruments can integrate pathogen-specific reagents into established workflows instead of introducing an entirely separate diagnostic platform. Thermo Fisher therefore primarily competes through laboratory standardization, molecular-testing infrastructure, and compatibility with high-throughput PCR workflows.

 

Innocreate Bioscience’s Role in the Shrimp Disease Diagnostics Market

Innocreate Bioscience occupies the rapid field-testing segment through its WSSV RP Rapid Test Kit. WOAH lists the product in its register of diagnostic kits for qualitative detection of WSSV infection in shrimp.

Its portfolio addresses farms and field personnel that need faster screening without immediate access to centralized PCR infrastructure. WOAH's evaluation indicates stronger performance when infection levels are moderate to high or shrimp are symptomatic, which means the product complements rather than fully substitutes highly sensitive PCR surveillance. This positioning gives Innocreate exposure to decentralized farm screening while molecular laboratories retain an advantage for low-level infection detection and confirmatory work.

 

Analyst Perspective: Why Is Shrimp Disease Diagnostics Becoming a Recurring Biosecurity Operating Expense?

The biggest growth opportunity in shrimp diagnostics is shifting testing earlier in the production cycle. Instead of only testing after disease outbreaks, farms are increasingly screening at key stages like broodstock quarantine, hatchery production, post-larvae selection, stocking, and routine pond monitoring. This helps detect problems early and reduces crop losses.

India shows how this is being implemented at scale, with national disease surveillance programs, mandatory farm and hatchery registration, SPF broodstock requirements, and routine PCR-based monitoring making diagnostics a standard part of aquaculture operations.

As shrimp diseases like WSSV, EHP, AHPND, and others continue to spread, demand is rising for multiplex tests that can detect multiple pathogens in a single run, saving time and reducing repeated sampling. At the same time, new assays are being developed to keep up with emerging diseases.

However, cost and access remain challenges, especially for small farms. Regular lab testing and sample transport can be expensive, while rapid field tests are cheaper and faster but less sensitive. WOAH evaluations highlight this trade-off between speed and accuracy.

Overall, the market is moving toward a layered system: rapid tests for on-farm screening, PCR and multiplex tools for routine monitoring, and advanced lab methods for confirmation. This shift is supporting strong market growth, with the Shrimp Disease Diagnostics Market expected to rise from USD 0.44 billion in 2025 to USD 0.87 billion by 2032, at a CAGR of 10.2%.

 

Shrimp Disease Diagnostics Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 0.44 Billion
Revenue Forecast in 2032	USD 0.87 Billion
Overall Growth Rate	CAGR of 10.2% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Diagnostic Method, By Disease Type, By End User, By Geography
By Diagnostic Method	PCR & qPCR, Isothermal Amplification, Immunoassays, Microscopy & Histopathology, Culture-Based & Biochemical Tests, Others
By Disease Type	White Spot Syndrome Virus [WSSV], Acute Hepatopancreatic Necrosis Disease [AHPND], Enterocytozoon hepatopenaei [EHP], Infectious Hypodermal and Hematopoietic Necrosis Virus [IHHNV], Yellow Head Virus [YHV], Other Shrimp Diseases
By End User	Shrimp Farms, Hatcheries, Diagnostic Laboratories, Research Institutes, Government & Regulatory Laboratories
By Region	Asia-Pacific, Latin America, North America, Europe, Middle East & Africa
Country Scope	India, Vietnam, Ecuador, U.S., Denmark, Saudi Arabia, and Other Key Shrimp-Producing and Diagnostic Markets
Market Drivers	Expansion of preventive disease surveillance, rising WSSV and EHP screening requirements, increasing adoption of PCR and multiplex pathogen testing, stronger hatchery and broodstock biosecurity requirements
Customization Option	Available upon request